This is a news story, published by Yahoo, that relates primarily to Keytruda news.
For more Keytruda news, you can click here:
more Keytruda newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
cancer treatments. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest immunotherapy Keytruda news, combination immunotherapy news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Merck Research LaboratoriesReuters
•79% Informative
Merck has stopped two late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers.
The company has been seeking to test the drug in combination with other treatments.
The drug faces loss of patent protection at the end of the decade .
Merck: "Unmet needs remain across different types of cancer and stages of disease".
VR Score
90
Informative language
98
Neutral language
42
Article tone
formal
Language
English
Language complexity
65
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links